---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-021573"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T22:57:49.261355+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CorMedix reports Q4 2023 net loss $14.8M; FDA approved DefenCath; launch April 2024

## Summary
- Net loss Q4 2023 $14.8M ($0.26/sh) vs $8.2M ($0.20/sh) Q4 2022; operating expenses $15.7M.
- Full year 2023 net loss $46.3M ($0.91/sh) vs $29.7M ($0.74/sh) in 2022.
- FDA approved DefenCath Nov 15, 2023; commercial launch in inpatient setting planned April 15, 2024.
- CMS TDAPA application under review; targeting July 1, 2024 outpatient launch.
- Cash and short-term investments $76.0M at Dec 31, 2023; sufficient for at least 12 months.

## SEC filing metadata
- accession: 0001213900-24-021573
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390024021573/0001213900-24-021573-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390024021573/ea0201559-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-021573
- JSON: https://secwatch.observer/filing/0001213900-24-021573.json
- Plain text: https://secwatch.observer/filing/0001213900-24-021573.txt

## Key facts
- Earnings Releases
  CorMedix Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income $46.3 million, or $0.91 per share, EPS $0.91 per share.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Net income: $46.3 million, or $0.91 per share
  - EPS: $0.91 per share
  - Result: reported results
  source text: For the fourth quarter of 2023, CorMedix recorded a net loss of $14.8 million, or $0.26 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1410098/000121390024021573/0001213900-24-021573-index.htm
- Earnings Releases
  CorMedix Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income $46.3 million, or $0.91 per share, EPS $0.91 per share.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Net income: $46.3 million, or $0.91 per share
  - EPS: $0.91 per share
  - Result: reported results
  source text: For the year ended December 31, 2023, CorMedix recorded a net loss of $46.3 million, or $0.91 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1410098/000121390024021573/0001213900-24-021573-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.